Beam Therapeutics Inc. Debt Securities, Held-to-maturity, Sold, Realized Gain (Loss), Excluding Other-than-temporary Impairment
Beam Therapeutics Inc. (BEAM) reported Debt Securities, Held-to-maturity, Sold, Realized Gain (Loss), Excluding Other-than-temporary Impairment of $0 for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-11.
Discontinued › Income Statement › Other Income
us-gaap:HeldtomaturitySecuritiesSoldSecurityRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2021-05-11
- Beam Therapeutics Inc. debt securities, held-to-maturity, sold, realized gain (loss), excluding other-than-temporary impairment for the quarter ending 2021-03-31 was $0.00.
- Beam Therapeutics Inc. debt securities, held-to-maturity, sold, realized gain (loss), excluding other-than-temporary impairment for the quarter ending 2020-12-31 was $0.00.
- Beam Therapeutics Inc. debt securities, held-to-maturity, sold, realized gain (loss), excluding other-than-temporary impairment for the quarter ending 2020-09-30 was $0.00.
- Beam Therapeutics Inc. debt securities, held-to-maturity, sold, realized gain (loss), excluding other-than-temporary impairment for the quarter ending 2020-06-30 was $0.00.
- Beam Therapeutics Inc. debt securities, held-to-maturity, sold, realized gain (loss), excluding other-than-temporary impairment for fiscal 2020 was $0.00.
- Beam Therapeutics Inc. debt securities, held-to-maturity, sold, realized gain (loss), excluding other-than-temporary impairment for fiscal 2019 was $0.00.
| Period end | Debt Securities, Held-to-maturity, Sold, Realized Gain (Loss), Excluding Other-than-temporary Impairment 3 month | Debt Securities, Held-to-maturity, Sold, Realized Gain (Loss), Excluding Other-than-temporary Impairment 6 month | Debt Securities, Held-to-maturity, Sold, Realized Gain (Loss), Excluding Other-than-temporary Impairment 9 month | Debt Securities, Held-to-maturity, Sold, Realized Gain (Loss), Excluding Other-than-temporary Impairment 12 month |
|---|---|---|---|---|
| 2021-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-05-11 | $0.00 derived: sum of 3 quarters · filed 2021-05-11 | $0.00 derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $0.00 derived: sum of 2 quarters · filed 2021-03-15 | $0.00 derived: sum of 3 quarters · filed 2021-03-15 | $0.00 10-K · filed 2021-03-15 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $0.00 derived: sum of 2 quarters · filed 2020-11-10 | $0.00 10-Q · filed 2020-11-10 | $0.00 derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $0.00 10-Q · filed 2020-08-12 | $0.00 derived: sum of 3 quarters · filed 2021-05-11 | $0.00 derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-05-11 | $0.00 derived: sum of 3 quarters · filed 2021-05-11 | $0.00 derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $0.00 derived: sum of 2 quarters · filed 2021-03-15 | $0.00 derived: sum of 3 quarters · filed 2021-03-15 | $0.00 10-K · filed 2021-03-15 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $0.00 derived: sum of 2 quarters · filed 2020-11-10 | $0.00 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $0.00 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |